TrialAlzheimer's research & therapy2019

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.

Lutz Frölich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.